EBFAHF-2

Phase 1Small molecule

IIcahn School of Medicine at Mount Sinai

EBFAHF-2 is one of 53 small molecule programs targeting Crohn's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseActive, not recruiting

Crohn's DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Approved

21 2

Trexall

Jazz Pharmaceuticals

Approved

1 3

Levulan

Sun Pharmaceutical Industries, Inc.

Rocaltrol

Medrol

Calciferol

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 8

Lamprene

Rayos

2 10

Tremfya

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT03992469·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EBFAHF-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EBFAHF-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EBFAHF-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIcahn School of Medicine at Mount Sinai

EBFAHF-2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News